Journal of acquired immune deficiency syndromes (1999) · 2026
Use of Long-acting Injectable Antiretroviral Therapy in Kidney and Liver Transplant Recipients with HIV.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Durand Christine, Hussain Sarah, Kopf Sabrina, Mehta Shikha, Eleti Navya, Rana Meenakashi, Stosor Valentina, Florman Sander, Hand Jonathan, Erdmann Nathaniel
Аннотация
BACKGROUND: The 2013 HIV Organ Policy Equity Act facilitated HIV-to-HIV organ transplants, enabling people with HIV to receive transplants more quickly. However, managing drug interactions between ART and immunosuppressive regimens remains a challenge.
OBJECTIVE: This study assesses the safety and effectiveness of cabotegravir/rilpivirine (CAB/RPV), an injectable ART, in maintaining HIV virologic suppression in kidney and liver transplant recipients.
METHODS: A retrospective review of three clinical studies evaluated CAB/RPV in transplant recipients with HIV. Participants had suppressed HIV RNA levels before transplant and were monitored post-transplant every six months.
RESULTS: Nine transplant recipients (7 kidney, 2 liver) received CAB/RPV. All maintained HIV suppression, with no allograft loss, although one liver recipient experienced acute rejection. One participant died from trauma unrelated to the transplant or HIV.
CONCLUSION: CAB/RPV shows promise for HIV management after transplantation. Further research is needed using a larger cohort.
OBJECTIVE: This study assesses the safety and effectiveness of cabotegravir/rilpivirine (CAB/RPV), an injectable ART, in maintaining HIV virologic suppression in kidney and liver transplant recipients.
METHODS: A retrospective review of three clinical studies evaluated CAB/RPV in transplant recipients with HIV. Participants had suppressed HIV RNA levels before transplant and were monitored post-transplant every six months.
RESULTS: Nine transplant recipients (7 kidney, 2 liver) received CAB/RPV. All maintained HIV suppression, with no allograft loss, although one liver recipient experienced acute rejection. One participant died from trauma unrelated to the transplant or HIV.
CONCLUSION: CAB/RPV shows promise for HIV management after transplantation. Further research is needed using a larger cohort.